请使用支持JavaScript的浏览器!
主营:抗癌化学试剂和激酶抑制剂
banner
当前位置: 首页 > 产品中心 > Apoptosis > MedKoo/Pomalidomidefeatured/1g/202310

MedKoo/Pomalidomidefeatured/1g/202310

  • 产品编号: 202310
  • 美  元  价: $150.00
  • 市  场  价: ¥3000.00
  • 品       牌:
  • 产       地: 美国(厂家直采)
  • 公       司: MedKoo Biosciences, Inc
  • 产品分类:
  • 公司分类: Apoptosis
MedKoo/Pomalidomidefeatured/1g/202310
  • MedKoo/Pomalidomidefeatured/1g/202310
商品介绍

Pomalidomide
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#:202310

CAS#:19171-19-8

Description:Pomalidomide, also known as CC4047, is an orally bioavailable derivative of thalidomide with potential immunomodulating, antiangiogenic and antineoplastic activities. Although its exact mechanism of action has yet to be fully elucidated, pomalidomide appears to inhibit TNF-alpha production, enhance the activity of T cells and natural killer (NK) cells and enhance antibody-dependent cellular cytotoxicity (ADCC). Pomalidomide was approved on February 8, 2013 as a treatment for relapsed and refractory multiple myeloma.

Price and Availability

SizePriceShipping out timeQuantity
1gUSD 150Same day
2gUSD 250Same day
5gUSD 450Same day
10gUSD 750Same day
20gUSD 1250Same day
50gUSD 1950Same day
100gUSD 3250Same day
200gUSD 4450Same day
Inquire bulk and customized quantity

Pricing updated 2021-01-23.Prices are subject to change without notice.

Pomalidomide, purity > 98%, is in stock. The same day shipping out after order is received.

Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 202310Name: PomalidomideCAS#: 19171-19-8Chemical Formula: C13H11N3O4Exact Mass: 273.07496Molecular Weight: 273.24Elemental Analysis:C, 57.14; H, 4.06; N, 15.38; O, 23.42

Synonym:CC4047; CC 4047; CC-4047; Pomalidomide. Brand name: Pomalyst.

IUPAC/Chemical Name:4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione

InChi Key:UVSMNLNDYGZFPF-UHFFFAOYSA-N

InChi Code:InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)

SMILES Code:O=C1N(C(CC2)C(NC2=O)=O)C(C3=C1C=CC=C3N)=O

Technical Data

Appearance:
white solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Certificate of Analysis:
View CoA: current batch, Lot# A8T06K23

QC Data:
View QC data: current batch, Lot#A8T06K23

Safety Data Sheet (SDS):
View Safety Data Sheet (SDS)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001

References

1: Elkinson S, McCormack PL. Pomalidomide: FirstGlobal Approval. Drugs. 2013 Apr 10. [Epub ahead of print] PubMed PMID:23572409.

2: Traynor K. Pomalidomide approved for multiple myeloma. Am J HealthSyst Pharm. 2013 Mar 15;70(6):474. doi: 10.2146/news130020. PubMed PMID:23456394.

3: Henry JY, Labarthe MC, Meyer B, Dasgupta P, Dalgleish AG, GalustianC. Enhanced cross-priming of naive CD8+ T cells by DCs treated by theIMiDs(®) immunomodulatory compounds Lenalidomide and Pomalidomide.Immunology. 2013 Feb 1. doi: 10.1111/imm.12087. [Epub ahead of print]PubMed PMID: 23374145.

4: Ellis PM, Jungnelius U, Zhang J, Fandi A, Beck R, Shepherd FA. APhase I Study of Pomalidomide (CC-4047) in Combination with Cisplatinand Etoposide in Patients with Extensive-Stage Small-Cell Lung Cancer. JThorac Oncol. 2013 Apr;8(4):423-8. doi: 10.1097/JTO.0b013e318282707b.PubMed PMID: 23370364.

5: Leleu X, Attal M, Arnulf B, Moreau P, Traulle C, Marit G, Mathiot C,Petillon MO, Macro M, Roussel M, Pegourie B, Kolb B, Stoppa AM, HennacheB, Bréchignac S, Meuleman N, Thielemans B, Garderet L, Royer B, Hulin C,Benboubker L, Decaux O, Escoffre-Barbe M, Michallet M, Caillot D,Fermand JP, Avet-Loiseau H, Facon T; Intergroupe Francophone du Myélome.Pomalidomide plus low-dose dexamethasone is active and well tolerated inbortezomib and lenalidomide-refractory multiple myeloma: IntergroupeFrancophone du Myelome 2009-02. Blood. 2013 Mar 14;121(11):1968-75. doi:10.1182/blood-2012-09-452375. Epub 2013 Jan 14. PubMed PMID: 23319574.

6: Richardson PG, Siegel D, Baz R, Kelley SL, Munshi NC, Laubach J,Sullivan D, Alsina M, Schlossman R, Ghobrial IM, Doss D, Loughney N,McBride L, Bilotti E, Anand P, Nardelli L, Wear S, Larkins G, Chen M,Zaki MH, Jacques C, Anderson KC. Phase 1 study of pomalidomide MTD,safety, and efficacy in patients with refractory multiple myeloma whohave received lenalidomide and bortezomib. Blood. 2013 Mar14;121(11):1961-7. doi: 10.1182/blood-2012-08-450742. Epub 2012 Dec 14.PubMed PMID: 23243282.

7: Hoffmann M, Kasserra C, Reyes J, Schafer P, Kosek J, Capone L, PartonA, Kim-Kang H, Surapaneni S, Kumar G. Absorption, metabolism andexcretion of [14C]pomalidomide in humans following oral administration.Cancer Chemother Pharmacol. 2013 Feb;71(2):489-501. doi:10.1007/s00280-012-2040-6. Epub 2012 Dec 1. PubMed PMID: 23203815;PubMed Central PMCID: PMC3556473.

8: Bolzoni M, Storti P, Bonomini S, Todoerti K, Guasco D, Toscani D,Agnelli L, Neri A, Rizzoli V, Giuliani N. Immunomodulatory drugslenalidomide and pomalidomide inhibit multiple myeloma-inducedosteoclast formation and the RANKL/OPG ratio in the myelomamicroenvironment targeting the expression of adhesion molecules. ExpHematol. 2012 Nov 23. doi:pii: S0301-472X(12)00542-5.10.1016/j.exphem.2012.11.005. [Epub ahead of print] PubMed PMID:23178378.

9: Ruchelman AL, Man HW, Zhang W, Chen R, Capone L, Kang J, Parton A,Corral L, Schafer PH, Babusis D, Moghaddam MF, Tang Y, Shirley MA,Muller GW. Isosteric analogs of lenalidomide and pomalidomide: synthesisand biological activity. Bioorg Med Chem Lett. 2013 Jan 1;23(1):360-5.doi: 10.1016/j.bmcl.2012.10.071. Epub 2012 Oct 27. PubMed PMID:23168019.

10: Zhu YX, Kortuem KM, Stewart AK. Molecular mechanism of action ofimmune-modulatory drugs thalidomide, lenalidomide and pomalidomide inmultiple myeloma. Leuk Lymphoma. 2013 Apr;54(4):683-7. doi:10.3109/10428194.2012.728597. Epub 2012 Sep 28. PubMed PMID: 22966948.

品牌介绍


MedKoo是世界领先的供应商之一的抗癌化学试剂和激酶抑制剂。我们制造、销售和分发高质量的抗癌小分子肿瘤学研究试剂。我们的使命是建立世界上最全面的抗癌小分子的集合。我们也为医药行业提供高质量的研究服务、医学研究机构和学术机构。我们致力于提供优质的服务。

MedKoo是世界领先的供应商之一的抗癌化学试剂和激酶抑制剂。我们制造、销售和分发高质量的抗癌小分子肿瘤学研究试剂。我们的使命是建立世界上最全面的抗癌小分子的集合。我们也为医药行业提供高质量的研究服务、医学研究机构和学术机构。我们致力于提供优质的服务和分子有竞争力的价格。MedKoo是您可靠的合作伙伴采购药物发现和药物分子。




蚂蚁淘(ebiomall)作为一家生命科学领域的垂直电商平台,公司专注生物医学科研用品的全球导购和品牌推广,为海内外厂方与代理经销商搭建跨境贸易系统和交流平台。产品齐全,200+分类,1000+品牌,500万+产品信息。100%正品,专业售后,到货快,在线下单, 简单轻松,节省科学家宝贵的科研时间。为您竭诚服务!

【订购】蚂蚁淘生物科技  联系方式:4000-520-616

更多产品,更多优惠!请联系我们!

苏州蚂蚁淘生物科技有限公司

免费热线:4000-520-616

官网:https://www.ebiomall.cn/



MedKoo,由化学家和药学家陈清奇博士。北卡罗莱纳州的研究三角区(Research Triangle Park, 简称 RTP ),是一家以研发、生产和销售小分子抗癌化合物为主的医药科技公司,该公司的业务范围主要是为全球所有从事抗癌药物研究和开发的制药公司,高校,研究院所,政府相关机构提供与抗癌药物分子相关的产品、试剂和技术服务。
中文名MedKoo中    文美帝药库医药科技公司创立于2008年总部位于美国东海岸
自营商城图标
厂家直采
全球直采模式 正品优价
正品保障图标
正品保障
厂家直发 有线跟踪
解放采购图标
正规清关
CIF100%正规报关,提供发票
及时交付图标
及时交付
限时必达 不达必赔
在线客服
客服电话

4000-520-616

0512-67156496